Loading…
TriSalus Life Sciences, Inc. is projected to rise to $5.90 by 2027, a +30% move from its current price of $4.54. TLSI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $4.39 | $4.54 | $4.70 | +0.04% |
| Aug 4 | $4.33 | $4.54 | $4.76 | +0.08% |
| Aug 5 | $4.29 | $4.55 | $4.82 | +0.11% |
| Aug 6 | $4.25 | $4.55 | $4.86 | +0.15% |
| Aug 7 | $4.22 | $4.55 | $4.90 | +0.19% |
| Aug 8 | $4.19 | $4.55 | $4.94 | +0.23% |
| Aug 9 | $4.17 | $4.55 | $4.97 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.17 | $4.55 | $4.97 | +0.27% |
| Week 2 | $4.03 | $4.56 | $5.17 | +0.53% |
| Week 3 | $3.92 | $4.58 | $5.34 | +0.80% |
| Week 4 | $3.84 | $4.59 | $5.48 | +1.07% |
| Week 5 | $3.77 | $4.60 | $5.61 | +1.34% |
| Week 6 | $3.71 | $4.61 | $5.73 | +1.61% |
| Week 7 | $3.66 | $4.63 | $5.85 | +1.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer.
The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff.
The company was founded in 2009 and is headquartered in Westminster, Colorado.
TriSalus Life Sciences, Inc. (TLSI) is a Healthcare company currently priced at $4.56 per share. Its market capitalization stands at $280.06M, and it holds a rank of 3343.
The stock sits in the small- to mid-cap segment of the market, reflecting its current market position and size.
The price outlook, based on the provided year-by-year forecast, shows a path of rising averages over time, with aligns from a near-term level around the current price toward substantially higher levels by the end of the forecast horizon. For example, the average forecast climbs from $4.56 in 2026 to $13.18 by 2030 and extends to higher levels through 2050, signaling meaningful upside albeit with inherent uncertainty.
Overall, the forecast paints a bullish long-run trajectory with notable upside potential across multiple years.
A major floor 44.5% below — a decisive break under it would weaken the trend.
The nearest floor, 18.9% below — buyers have tended to step in here.
The nearest ceiling, 4.4% above — a clean break opens room to run.
A major ceiling 18.5% above — clearing it would confirm fresh momentum.
Key TLSI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TLSI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.43 | Buy | $4.45 | Buy |
| MA 10 | $4.35 | Buy | $4.37 | Buy |
| MA 20 | $4.23 | Buy | $4.29 | Buy |
| MA 50 | $3.96 | Buy | $4.16 | Buy |
| MA 100 | $4.04 | Buy | $4.24 | Buy |
| MA 200 | $4.78 | Sell | $4.52 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.50 | Neutral |
| Stoch RSI (14) | 93.32 | Sell |
| CCI (20) | 139.38 | Buy |
| Williams %R (14) | -3.85 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 10.73 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 96.15 | Sell |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | 0.17 | Buy |
| Ultimate (7,14,28) | 73.86 | Sell |
| Momentum (10) | 0.25 | Buy |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 4.52 | Buy |
| ADX (14) | 11.88 | Neutral |
| ATR (14) | 0.12 | Info |
The near-term technical picture is bullish, with an RSI of 60 supporting positive momentum. The stock trades above the 50-day moving average of $3.93 and approaches the 200-day moving average near $4.78 as a guide for trend.
Key near-term support sits at $3.68 and resistance at $4.74, framing a shallow range around the current price. The 30-day price range spans from $3.63 to $5.73, indicating room for upside moves within a tight consolidation band. The near-term volatility measure sits at 70 for annualized volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.52 | $4.54 | $5.80 | 0% | Neutral | |
| $4.61 | $5.90 | $8.04 | +30% | Bullish | |
| $6.15 | $8.16 | $11.63 | +80% | Bullish | |
| $7.81 | $10.67 | $15.75 | +135% | Bullish | |
| $9.30 | $13.04 | $19.80 | +187% | Bullish | |
| $9.52 | $13.68 | $21.30 | +201% | Bullish | |
| $10.26 | $15.07 | $24.01 | +232% | Bullish | |
| $11.92 | $17.88 | $29.06 | +294% | Bullish | |
| $14.24 | $21.81 | $36.10 | +380% | Bullish | |
| $17.57 | $27.42 | $46.17 | +504% | Bullish | |
| $25.87 | $44.12 | $79.78 | +872% | Bullish | |
| $46.91 | $93.66 | $187.68 | +19.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.52 | $4.54 | $5.43 | +0.00% |
| September 2026 | $3.77 | $4.49 | $5.51 | -1.17% |
| October 2026 | $3.91 | $4.70 | $5.85 | +4.76% |
| November 2026 | $3.93 | $4.75 | $5.97 | +1.00% |
| December 2026 | $3.75 | $4.56 | $5.80 | -3.85% |
Click any year to see its month-by-month TLSI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
TriSalus Life Sciences, Inc.'s 2026 outlook centres on $4.54, within a $2.52 to $5.80 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, TLSI could reach as high as $8.04, with a base case around $5.90 and support toward $4.61 — roughly +30% from $4.54. Momentum favours further upside here.
Expect TLSI to range from $6.15 to $11.63 through 2028. The $8.16 average target implies a +80% move from current prices. That is up +38% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The TLSI price prediction for 2029 points to an average of $10.67 (low $7.81, high $15.75) — a potential gain of +135% on today's $4.54. Momentum favours further upside here.
In 2030, TLSI is projected to trade between $9.30 and $19.80, averaging $13.04 — a potential gain of +187% from today's $4.54. That is up +22% on the projected 2029 average. Buyers look set to stay in control over this stretch.
TriSalus Life Sciences, Inc.'s 2031 outlook centres on $13.68, within a $9.52 to $21.30 range. That is up +5% on the projected 2030 average. That marks a +201% change versus current levels. Momentum favours further upside here.
By 2032, TLSI could reach as high as $24.01, with a base case around $15.07 and support toward $10.26 — roughly +232% from $4.54. Buyers look set to stay in control over this stretch.
Expect TLSI to range from $11.92 to $29.06 through 2033. The $17.88 average target implies a +294% move from current prices. That is up +19% on the projected 2032 average. Momentum favours further upside here.
The TLSI price prediction for 2034 points to an average of $21.81 (low $14.24, high $36.10) — a potential gain of +380% on today's $4.54. Buyers look set to stay in control over this stretch.
In 2035, TLSI is projected to trade between $17.57 and $46.17, averaging $27.42 — a potential gain of +504% from today's $4.54. That is up +26% on the projected 2034 average. Momentum favours further upside here.
TriSalus Life Sciences, Inc.'s 2040 outlook centres on $44.12, within a $25.87 to $79.78 range. That is up +61% on the projected 2035 average. That marks a +872% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, TLSI could reach as high as $187.68, with a base case around $93.66 and support toward $46.91 — roughly +19.6x from $4.54. Momentum favours further upside here.
Investing $1,000 in TLSI today (≈ 220.264317 TLSI) could be worth
$20,630.1
+$19,630.1 (+1963%) by 2050 · US Dollar
Based on the average projected TLSI price of $93.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TLSIwould be worth at today's price.
$1,000 invested in TLSI on Jul 31, 2025 (≈ 236.406618 TLSI) would be worth
$1,073.29
+$73.29 (+7.3%) today · 1.07× · US Dollar
Based on a TLSI entry price of $4.23 vs. today's $4.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.22 | $1,075.83 | +7.6% |
| 1 month ago | $4.46 | $1,017.94 | +1.8% |
| 3 months ago | $4.39 | $1,034.17 | +3.4% |
| 6 months ago | $5.11 | $888.45 | -11.2% |
| 1 year ago | $4.23 | $1,073.29 | +7.3% |
| All time (5.0y) ago | $9.73 | $466.6 | -53.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TLSI forecast.
Our base-case forecast reaches $9.10 around 2029.
Implied market cap at $9.10: $558.89M
The multi-year forecast shows a continued rise in expected prices and rising ROIs after 2026. The 2026 forecast is min $2.52, avg $4.56, max $5.81 with a 0 ROI and a neutral sentiment. From 2027 onward, sentiment turns bullish with min/avg/max values of $4.62/$5.93/$8.13 (ROI 30.1), $6.17/$8.23/$11.80 (ROI 80.4), and $7.82/$10.75/$15.98 (ROI 135.8).
By 2030, the forecast shows min $9.33, avg $13.18, max $20.16 with a 189 ROI and bullish sentiment. The trajectory continues to rise through 2035 ($17.49/$27.61/$46.95; ROI 505.5) and into the long horizon, with 2040 having a min of $25.61, avg $44.35, max $81.11 (ROI 872.6) and 2050 reaching min $45.84, avg $93.69, max $190.20 (ROI 1954.6).
These figures describe an overall bullish long-term view, with substantial upside potential across decades while recognizing that forecasts are not guarantees and carry uncertainty.
Tap a question to reveal the answer.
Min: $9.33; Avg: $13.18; Max: $20.16; ROI: 189; Sentiment: BULLISH.
The forecast shows rising averages and bullish sentiment from 2027 onward, with increasing ROIs (e.g., 2027 ROI 30.1; 2028 ROI 80.4; 2029 ROI 135.8; 2030 ROI 189; 2031 ROI 201; 2050 ROI 1954.6). These are estimates, not guarantees.
Yes. The 2030 forecast max is $20.16.
Current price: $4.56. Market cap: $280.06M.
Bullish sentiment with RSI(14) at 60, SMA(50) at $3.93, SMA(200) at $4.78, a support level at $3.68, and a resistance at $4.74. The 30-day range is $3.63 to $5.73, with annualized volatility at 70.
TriSalus Life Sciences, Inc. Community Discussion
0Share your TriSalus Life Sciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.